Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
SPRUCE BIOSCIENCES, INC. (SPRB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/30/2023 |
SC 13D/A
| RiverVest Venture Fund III, L.P. reports a 8.6% stake in SPRUCE BIOSCIENCES, INC. |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/28/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/27/2023 |
SC 13G
| 5AM Opportunities II, L.P. reports a 10% stake in Spruce Biosciences, Inc. |
| 02/23/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 9.2% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following ter...",
"COMMON STOCK PURCHASE WARRANT SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicat...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement , dated as of February 8, 2023, is made by and among Spruce Biosciences, Inc., a Delaware corporation , and the Purchasers listed on hereto, together with their permitted transferees . Recitals A. The Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act and/or Rule 506 of Regulation D as promulgated by the SEC under the Securities Act. B. The Purchasers, severally, and not jointly, desire to purchase from the Company, and the Company desires to sell to the Purchasers, upon the terms and conditions stated in this Agreement, shares of the Company’s common stock, par value $0.0001 per share , to certain Purch..." |
|
| 01/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements... |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
SC 13D/A
| Novo Holdings A/S reports a 19.2% stake in Spruce Biosciences, Inc. |
| 08/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
8-K
| Quarterly results |
| 04/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|